1. LL-00066471, a novel positive allosteric modulator of α7 nicotinic acetylcholine receptor ameliorates cognitive and sensorimotor gating deficits in animal models: Discovery and preclinical characterization.
- Author
-
Verma, Mahip K., Goel, Rajan N., Bokare, Anand M., Dandekar, Manoj P., Koul, Sarita, Desai, Sagar, Tota, Santoshkumar, Singh, Nilendra, Nigade, Prashant B., Patil, Vinod B., Modi, Dipak, Mehta, Maneesh, Gundu, Jayasagar, Walunj, Sameer S., Karche, Navnath P., Sinha, Neelima, Kamboj, Rajender K., and Palle, Venkata P.
- Subjects
- *
NICOTINIC acetylcholine receptors , *CHOLINERGIC receptors , *NEUROLOGICAL disorders , *STARTLE reaction , *CONOTOXINS , *ACOUSTIC reflex , *ANIMAL models in research , *APOMORPHINE - Abstract
α7 nicotinic acetylcholine receptor (α7 nAChR) is an extensively validated target for several neurological and psychiatric conditions namely, dementia and schizophrenia, owing to its vital roles in cognition and sensorimotor gating. Positive allosteric modulation (PAM) of α7 nAChR represents an innovative approach to amplify endogenous cholinergic signaling in a temporally restricted manner in learning and memory centers of brain. α7 nAChR PAMs are anticipated to side-step burgeoning issues observed with several clinical-stage orthosteric α7 nAChR agonists, related to selectivity, tolerance/tachyphylaxis, thus providing a novel dimension in therapeutic strategy and pharmacology of α7 nAChR ion-channel. Here we describe a novel α7 nAChR PAM, LL-00066471, which potently amplified agonist-induced Ca2+ fluxes in neuronal IMR-32 neuroblastoma cells in a α-bungarotoxin (α-BTX) sensitive manner. LL-00066471 showed excellent oral bioavailability across species (mouse, rat and dog), low clearance and good brain penetration (B/P ratio > 1). In vivo , LL-00066471 robustly attenuated cognitive deficits in both procognitive and antiamnesic paradigms of short-term episodic and recognition memory in novel object recognition task (NORT) and social recognition task (SRT), respectively. Additionally, LL-00066471 mitigated apomorphine-induced sensorimotor gating deficits in acoustic startle reflex (ASR) and enhanced antipsychotic efficacy of olanzapine in conditioned avoidance response (CAR) task. Further, LL-00066471 corrected redox-imbalances and reduced cortico-striatal infarcts in stroke model. These finding together suggest that LL-00066471 has potential to symptomatically alleviate cognitive deficits associated with dementias, attenuate sensorimotor gating deficits in schizophrenia and correct redox-imbalances in cerebrovascular disorders. Therefore, LL-00066471 presents potential for management of cognitive impairments associated with neurological and psychiatric conditions. Image 1 • α7 nAChR signaling is crucial for human sensorimotor-gating, cognition and regulation of neuroinflammation. • α7 nAChR activation attenuates cognitive deficits. α7 nAChR PAMs may overcome limitations of orthosteric agonists. • LL-00066471, a novel orally bioavailable, brain-permeable α7 nAChR PAM shows procognitive and antidementia potential. • LL-00066471 complements neuroleptic drugs, reduces neuronal oxidative stress and infarct formation in stroke models. • Results support utility of LL-00066471 in management of cognitive impairments in several neuropsychiatric indications. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF